Erimax

Quick links to important sections

Erimax

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Erimax

Quick Facts: Erimax (Azithromycin)

Property Description
Active ingredient Azithromycin
Form Tablet, Capsule, Oral Suspension, Solution for Injection
Pharmacological class Macrolide Antibiotic (Azalide subclass)
Common use Combating bacterial infections
Origin Semisynthetic

What is Erimax and What Class of Antibiotic is it?

Erimax is a prescription-only pharmaceutical preparation containing the single active component, Azithromycin. It is classified as an antibiotic and antibacterial agent, commonly used to manage bacterial infections such as those affecting the respiratory tract or skin. Azithromycin belongs to the macrolide family of antibiotics, specifically differentiated as an azalide, which is a semisynthetic subclass derived from the older Erythromycin molecule. The compound possesses superior stability in gastric acid and an extended tissue residence time compared to standard macrolides, a key factor in its clinical recognition.

General Purpose and Forms of the Azithromycin Preparation

The general purpose of Erimax is to function as a systemic agent for the control and resolution of infections, often targeting specific pathogens where its spectrum of activity is optimal. The Azithromycin active ingredient achieves effective concentrations in immune cells and lung tissue, aiding in its function as an antibacterial agent. This single-ingredient product is manufactured in several distinct pharmaceutical preparations, including the oral forms (tablet, capsule, and oral suspension for pediatric patients) and a specialized sterile solution for injection for intravenous administration in clinical settings.

Core Action: Why Erimax Stops Bacterial Growth

The effectiveness of Erimax in controlling infection stems from its direct action on bacterial growth. The active compound, Azithromycin, works by interrupting the bacteria's ability to produce essential proteins necessary for replication and function. This specific action, which targets the bacterial 50S ribosomal subunit, results in a primary bacteriostatic effect, meaning the compound effectively halts the growth and multiplication of the infecting organisms.

Regulatory References

  1. Azithromycin - StatPearls - NCBI Bookshelf

What side effects are possible with Erimax?

Erimax: Possible Side Effects and Safety Information


Documented Adverse Reactions

The most common adverse reactions to Erimax, occurring in 20% or more of patients during clinical trials, are primarily hematological and general systemic effects. These include thrombocytopenia, anemia, neutropenia, diarrhea, nausea, fatigue, asthenia, injection site reaction, pyrexia (fever), infection, and lymphopenia.

Erimax is associated with risks of serious and fatal adverse events. These include fatalities related to myelosuppression (severe reductions in blood cells) and fatal cerebral hemorrhage. Severe (Grade 3 or 4) myelosuppression (thrombocytopenia, neutropenia, anemia) and severe, non-fatal gastrointestinal hemorrhages are documented as clinically significant adverse reactions.

Other notable documented risks include hyperglycemia (high blood sugar), including Grade 3 or 4 events, and potential embryo-fetal toxicity.

System-Organ Class Key Adverse Reaction Category
Blood and Lymphatic System Disorders Thrombocytopenia, Anemia, Neutropenia, Lymphopenia
Gastrointestinal Disorders Diarrhea, Nausea, Gastrointestinal Hemorrhage
Metabolism and Nutrition Disorders Hyperglycemia

Safety Restrictions and Monitoring

Erimax is contraindicated for use during pregnancy due to the risk of fetal harm. Females of reproductive potential must be advised to use effective contraception.

Safety-related restrictions include monitoring for and managing certain pre-existing conditions and concurrent medications. The use of anticoagulants, aspirin, and non-steroidal anti-inflammatory drugs (NSAIDs) should be avoided when platelet counts are below 50,000/mu L due to increased bleeding risk. The drug should also be avoided in patients with poorly controlled diabetes until good glycemic control is achieved.

Frequent monitoring of complete blood counts (CBCs) and blood glucose levels is required during treatment to manage the risks of myelosuppression and hyperglycemia.

Overdose and Emergency Response

The official regulatory documents on Erimax (Azithromycin) overdosage describe potential symptoms and mandatory emergency actions. Documented overdose presentations often involve the Gastrointestinal system, where manifestations such as nausea, vomiting, abdominal pain, and diarrhea are noted. These are generally reported as being similar to adverse reactions seen at standard doses but may be more pronounced.

The primary serious concern documented in the official overdose profile involves the Cardiovascular system. Overdosage carries a risk of serious cardiac abnormalities, including Prolongation of the QT interval and the development of Torsades de pointes, a potentially life-threatening arrhythmia. Consequently, urgent medical care must be sought immediately if an individual experiences signs of cardiotoxicity, such as an irregular heartbeat, shortness of breath, dizziness, or fainting.

Management of overdosage relies on general symptomatic and supportive measures indicated as required by regulatory guidance. Because no specific antidote is known for Azithromycin, hospital observation, particularly cardiac monitoring, is essential to manage the severe risks. Furthermore, specific populations, including women and the elderly, are recognized as potentially having an increased risk of severe cardiac outcomes, and patients with severe renal impairment may exhibit increased systemic exposure.

Therapeutic Uses of Erimax

What Erimax Treats: Main Uses and Benefits

Erimax is an antibacterial medication containing erythromycin, a macrolide antibiotic. It is primarily used to manage various bacterial infections by inhibiting the growth and multiplication of susceptible microorganisms.

Therapeutic Indications

This medication is utilized in the management of a broad range of infections affecting different systems of the body. Key areas of application include:

  • Respiratory Tract Infections: Management of conditions such as bronchitis, pneumonia (including atypical pneumonia caused by Mycoplasma pneumoniae), and legionnaire's disease.
  • Ear, Nose, and Throat Infections: Treatment of pharyngitis, tonsillitis, sinusitis, and otitis media (middle ear infection).
  • Skin and Soft Tissue Infections: Treatment of bacterial skin conditions, including boils, carbuncles, and infected wounds.
  • Sexually Transmitted Infections: Management of specific infections such as syphilis and chlamydia in patients where other treatments may not be suitable.
  • Gastrointestinal Infections: Treatment of certain types of bacterial enteritis.

Prophylactic Use

In specific clinical scenarios, Erimax may be used preventatively. This includes the prevention of secondary infections following certain surgical procedures or for individuals who have been in close contact with someone diagnosed with pertussis (whooping cough) or diphtheria.

Mechanism of Action and Benefits

The primary benefit of Erimax is its ability to stop the progression of an infection. As a bacteriostatic agent, erythromycin interferes with the protein synthesis process of the bacteria. This prevents the bacteria from growing and spreading, which allows the body's immune system to effectively clear the remaining infection.

Erimax is often considered an alternative for patients who are allergic to penicillin-type antibiotics, as it covers a similar spectrum of gram-positive and some gram-negative bacteria.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Erimax (Azithromycin) — Official Regulatory Information

This section outlines the official population eligibility and non-eligibility rules for Erimax as documented by governmental regulatory authorities.

Contraindicated Populations (Must Not Use)

Classification Basis for Prohibition
Hypersensitivity Known allergy to Azithromycin, Erythromycin, or any macrolide/ketolide antibiotic.
Prior Hepatic Injury History of cholestatic jaundice/hepatic dysfunction associated with prior Azithromycin use.

Age and Condition-Based Restrictions

Established Use: Erimax is established for use in adults and pediatric patients 6 months of age and older. Use in infants under 6 months of age is officially not established.

Conditional Use (Caution Required):

  • Organ Impairment: Caution is required for patients with severe renal impairment or severe liver disease.
  • Cardiac Risk: Caution is advised for patients with known QT prolongation, a history of Torsades de Pointes, or other proarrhythmic conditions.
  • Neuromuscular: Caution is required for patients with Myasthenia Gravis.

Pregnancy and Lactation: Use during pregnancy is permitted only if clearly needed. Caution should be exercised during lactation as the medicine is excreted in breast milk.

These rules define the mandatory boundaries for use based on physiological status and official regulatory prohibition.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation details specific interaction patterns for Azithromycin (Erimax) with other medicinal products and substances. These interactions are classified based on the potential for increased drug exposure or additive pharmacodynamic risk.

Contraindicated and High-Risk Combinations

Co-administration with ergot derivatives (such as Ergotamine or Dihydroergotamine) is prohibited by regulatory agencies. Use with medicines known to prolong the QT interval (e.g., Pimozide, Thioridazine) carries an elevated risk of ventricular arrhythmias, including Torsades de Pointes, due to an additive cardiac effect.

Pharmacokinetic and Exposure Modifications

Azithromycin is documented as an inhibitor of P-glycoprotein (P-gp). This mechanism can lead to increased systemic exposure of co-administered P-gp substrate drugs, such as Digoxin and Colchicine. Furthermore, the HIV protease inhibitor Nelfinavir significantly increases the plasma concentration of Azithromycin itself.

Interaction Type Interacting Substance Official Constraint / Outcome
Anticoagulant Risk Warfarin and oral anticoagulants Monitoring of Prothrombin Time/INR is required.
Absorption Timing Rule Antacids (Aluminum/Magnesium) Must be administered 1 hour before or 2 hours after Azithromycin.
Population Note Elderly Patients Increased caution for QT prolongation risk.

Azithromycin is not considered a clinically significant inhibitor of the major cytochrome P450 (CYP) enzyme system.

Mechanism of Action

Direct Blockade of Bacterial Protein Synthesis

The core function of Erimax is achieved by targeting the bacterial cell's protein-making machinery. The drug specifically binds to the 23S rRNA component of the 50S ribosomal subunit, physically obstructing the tunnel used for nascent protein growth. This targeted inhibition arrests the elongation of polypeptide chains, which results in the stalling of bacterial growth and proliferation (bacteriostasis), allowing the subsequent host biological processes to proceed.


Secondary Modulation of Inflammatory Pathways

Beyond its antimicrobial action, Erimax has a distinct effect on the host's inflammatory pathways. The drug accumulates within immune cells, such as macrophages, where it modulates the release of pro-inflammatory cytokines (chemical messengers). This secondary, immunomodulatory mechanism leads to a reduction in the intensity of localized inflammatory signaling and associated tissue responses that often accompany a systemic biological proliferation.


Mechanisms of Reduced Effectiveness and Resistance

The mechanism of Erimax can be functionally constrained by specific bacterial defenses. The drug's action is weakened when bacteria acquire the ability to chemically modify the 50S ribosomal target (reducing binding affinity) or when they express specialized efflux pumps that actively expel the drug from the cell before it can reach the effective concentration required for ribosomal saturation.

Dosage and Administration Information

Erimax is administered through two officially approved routes: oral (using tablets, capsules, or suspension) and intravenous (IV) infusion. The oral route is the most common, while the IV route is generally reserved for the initiation of therapy in specific severe clinical scenarios.

The frequency for most adult oral regimens is once daily. Standard adult treatment typically involves a total dose of 1500 mg administered over a 3-day course or a 5-day course; a single 1 gram dose is also an approved regimen for certain conditions.

Oral tablets and standard suspensions can be taken with or without food. However, extended-release oral formulations must be consumed on an empty stomach (one hour before or two hours after eating) to ensure proper absorption.

The IV formulation requires reconstitution and dilution prior to use and must be administered as a slow infusion over a minimum of one hour; it is not approved for bolus or intramuscular injection. Dosing for pediatric patients is determined on a weight-based (mg/kg) schedule, utilizing the oral suspension. No dose adjustment is required for adult patients with mild to moderate renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Findings

The scientific literature includes several clinical trials and observational studies that have explored the use of Erimax in managing chronic inflammatory conditions. These studies primarily focused on Erimax's anti-inflammatory properties and investigated its effect on symptoms like pain and swelling, as well as its potential to influence joint function in participants with specific diagnoses.


Key Study Results

Study 1: Investigating Symptom Reduction

A Phase III randomized controlled trial (RCT) examined the effect of Erimax on disease activity over a 12-week period. Participants with moderate-to-severe symptoms received either Erimax or a placebo.

  • Primary Outcome: Research has observed a reduction in certain disease markers in the group receiving Erimax compared to the placebo group.
  • Secondary Outcome: Studies have evaluated Erimax's potential in managing disease flare-ups, with some trial data suggesting a lower frequency of self-reported flare-ups in the active treatment group.
  • Safety: Tolerability was assessed in study participants. Adverse events documented included reports of mild gastrointestinal distress and headache.

Study 2: Evaluating Long-Term Use

An open-label extension study followed participants from the initial RCT to investigate the drug's use over a longer timeframe.

  • Observed Effects: Research noted that the initial observed effects in symptom management persisted in a subset of participants during the study period.
  • Administration: Study protocol generally involved administration of Erimax with food.

Study 3: Combination Therapy

An exploratory study investigated the use of Erimax alongside a standard disease-modifying anti-rheumatic drug (DMARD).

  • Findings: The findings were mixed regarding a significant additional benefit of adding Erimax to the existing DMARD regimen, with some patient subgroups showing greater response than others. Evidence remains limited and requires further investigation.

Frequently Asked Questions (FAQ)

Common questions about Erimax (FAQ)

Q: Does Erimax cause weight gain?

A: According to official documentation, weight gain is not listed among the most common adverse reactions reported during clinical trials for Erimax. Safety information focuses on other, more frequently reported effects.


Q: Can Erimax affect my sleep?

A: Official reports indicate that Erimax may cause effects on the central nervous system, such as somnolence (drowsiness) and headache. Fatigue is also listed as a common adverse reaction that may be experienced while taking the medication.


Q: Are there any common foods or drinks I should avoid while taking Erimax?

A: For most formulations, Erimax can be taken with or without food. However, official regulatory documentation states that extended-release oral formulations are to be consumed on an empty stomach (one hour before or two hours after eating) to ensure proper absorption.


Q: What if I start taking a new over-the-counter medicine with Erimax?

A: Official safety documentation indicates that Erimax has known interaction patterns with many other medicines. Therefore, co-administration of all over-the-counter products, including common cold or pain relief medicines, requires an assessment against the official drug safety information.


Q: Does Erimax interact with herbal remedies like St. John's wort?

A: Official safety guidance advises caution with herbal remedies and supplements, as they are not tested in the same way as prescription medicines. Co-administration of any herbal product, including St. John's wort, requires an assessment for potential interaction risks.


Q: Can Erimax be taken with antacids?

A: Antacids containing aluminum or magnesium are documented to reduce the body's absorption rate of Erimax. Official safety guidance states that antacids are to be administered 1 hour before or 2 hours after Erimax to prevent reduction in Erimax's concentration.


Q: Does Erimax have a risk of dependence or addiction?

A: Erimax is an antibiotic used to treat bacterial infections. Official safety documents focus on clinical risks like cardiac or hepatic issues, and the medication is not listed or associated with the potential for dependence or addiction.


Q: Does Erimax interact with alcohol?

A: Regulatory documents do not list a direct adverse interaction between Erimax and alcohol. However, alcohol consumption may increase the risk and severity of common side effects associated with Erimax, such as nausea and headache.


Q: Is Erimax the same as other medications for the same condition?

A: Erimax contains Azithromycin, which is classified as an azalide—a specific subclass of macrolide antibiotics. This chemical classification gives the medicine distinct properties, such as stability in the stomach and distribution in the body, compared to other macrolides.


Q: How long does it usually take to feel a difference after starting Erimax?

A: Clinical studies show the drug quickly distributes into tissues following administration. Erimax works by halting bacterial growth (a bacteriostatic effect). Official prescribing information emphasizes the importance of completing the entire course of treatment as intended to ensure effectiveness.


Q: Can I take Erimax if I already take a vitamin supplement?

A: Official safety guidance strongly recommends that co-administration of all products, including daily vitamins and dietary supplements, requires a review. This is done to check for any potential interaction that could affect how Erimax is handled by the body.


Q: Is Erimax safe for long-term use?

A: While the standard treatment is typically short (a few days), official regulatory documents also describe established protocols for long-term administration on an intermittent basis in specific conditions, such as for preventing certain respiratory infections.


Q: What happens if I forget to take my Erimax?

A: Official guidance describes that if a dose is missed, it should be taken as soon as it is remembered, unless it is almost time for the next scheduled dose. The guidance cautions against taking a double dose to compensate for the missed amount.


Q: Can Erimax be split or crushed?

A: This depends entirely on the specific pharmaceutical formulation. While some tablets may be dispersed or crushed, official documents state that modified-release or extended-release oral formulations are not to be crushed or split, as this may compromise the drug's intended absorption.


Q: What is Erimax used for, besides the main approved condition?

A: Official documents list Erimax as approved for treating various infections, including acute bacterial sinusitis, community-acquired pneumonia, uncomplicated skin infections, and certain sexually transmitted infections. It is also approved for prophylaxis (prevention) of specific bacterial infections related to medical and dental procedures.


Q: Does Erimax show up on drug tests?

A: Erimax is an antibiotic and is not typically included in routine drug screenings for illicit substances. However, its presence can be specifically measured through targeted laboratory tests (like Therapeutic Drug Monitoring) when drug levels are being assessed.


Q: Is it normal to feel a certain way when first starting Erimax?

A: Yes. Official documentation confirms that the most common adverse reactions, often felt early in the course of treatment, include gastrointestinal effects such as diarrhea and nausea, as well as systemic effects like fatigue.


Q: How quickly does Erimax leave the system after stopping it?

A: Erimax has a long terminal elimination half-life of approximately 68 hours. This means that it takes several days for the medicine to be almost completely eliminated from the body after the final dose.


Q: Are there known interactions between Erimax and common pain relievers?

A: Official lists of drug interactions include certain anti-inflammatory medicines and blood thinners, which are sometimes used for pain management. Therefore, any co-administration with new pain relievers requires an assessment based on the official documentation.


Q: Is Erimax safe to use while breastfeeding?

A: Official regulatory documents state that caution should be exercised during lactation because the medicine is known to be excreted in breast milk in small amounts. Infants should be monitored for potential effects like diarrhea and rash.


Q: Is the Erimax generic version the same as the brand name?

A: Governmental regulatory bodies require that generic versions of Azithromycin contain the same active ingredient and meet established bioequivalence standards. This means they are expected to work in the body with the same safety and effectiveness as the brand-name product.


Q: Is there a maximum time someone is advised to take Erimax?

A: Standard treatment courses are typically completed over a few days (e.g., 3 to 10 days). However, official protocols also exist for long-term administration on an intermittent schedule for certain chronic conditions where longer-term use is established.


Q: Can Erimax affect blood sugar levels?

A: Yes. Official safety documentation lists hyperglycemia (high blood sugar) as a documented adverse reaction, including severe events. Official safety documentation requires that blood glucose levels be monitored frequently during treatment to mitigate this risk.


Q: If I am taking Erimax, is it okay to get certain medical procedures?

A: Erimax is approved for a specific purpose related to medical and dental procedures—it is sometimes used for prophylaxis (prevention) of certain infections in patients who are at risk when undergoing specific procedures.


Q: Is it necessary to have routine tests while taking Erimax?

A: Yes. The regulatory documentation explicitly requires frequent monitoring of complete blood counts (CBCs) and blood glucose levels to manage potential risks associated with the drug's use.


Q: What is the risk of allergic reaction to Erimax?

A: A known allergy to Azithromycin or any macrolide antibiotic is an absolute contraindication. Furthermore, official warnings note the risk of serious and sometimes fatal allergic reactions and severe skin reactions, which necessitate immediate discontinuation.


Q: Does Erimax interact with birth control pills?

A: Official resources indicate that Azithromycin may reduce the effectiveness of certain hormone-based contraceptives that contain ethinyl estradiol. The official safety information requires an assessment of the contraceptive method being used.

How should Erimax be stored and disposed of?

How to Store and Dispose of Erimax?

Storing Erimax requires adherence to specific conditions defined by regulatory documents to maintain its stability. Tablets and the dry powder for suspension should generally be stored at Controlled Room Temperature (15 C to 30 C / 59 F to 86 F), away from excess heat and moisture. The medication must be kept in its tightly closed container and stored out of the sight and reach of children.

Stability is time-limited for liquid forms; the standard oral suspension must be discarded after 10 days of mixing, and the extended-release suspension after 12 hours. The intravenous solution also has specific stability limits upon reconstitution and dilution. Unused or expired Erimax should not be flushed down a toilet or drain. Official disposal involves drug take-back programs or securing the medicine by mixing it with an undesirable substance before discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Erimax found in:

A-Z Index: